[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 701
Citations 0
News From the Food and Drug Administration
October 6, 2015

Another Option to Lower LDL

JAMA. 2015;314(13):1332. doi:10.1001/jama.2015.12087

A second drug in the new class of medications known as PCSK9 inhibitors has been approved for use in patients who can’t adequately reduce their low-density lipoprotein (LDL) cholesterol level with current treatments.

Evolocumab, marketed as Repatha, is approved for use with diet and maximally tolerated statin therapy in adults with heterozygous familiar hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia, or clinical atherosclerotic cardiovascular disease such as myocardial infarction or stroke who need to lower their LDL cholesterol (http://1.usa.gov/1KRg3o6).

First Page Preview View Large
First page PDF preview
First page PDF preview